Clinical trials: Cognition Disorders
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Multiple Sclerosis
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
Fampyra, a voltage-dependent potassium channel blocker, is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
- Trial name
- FAMILY (NCT03164018)
- Testing
- Fampridine
- Where
- Greece
- Volunteers
- 111 people
- Sponsor
- Genesis Pharma CNS & Specialty
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive…
- Trial name
- NCT04476017
- Testing
- SAGE-718
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Mild Cognitive Impairment
Efficacy of MEMORMAX in Subjects With MCI
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment.
- Trial name
- ABO-MEMO (NCT03581929)
- Testing
- Memormax
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Aboca Spa Societa' Agricola
Cognitive Disorders
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders
The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.
- Trial name
- NCT04295681
- Testing
- MMH-MAP
- Where
- 22 sites in Russia
- Volunteers
- 246 people
- Sponsor
- Materia Medica Holding
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02575482
- Testing
- SUVN-D4010
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild Cognitive Impairment
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.
- Trial name
- NCT05041790
- Testing
- Choline Alfoscerate
- Where
- South Korea
- Volunteers
- 418 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Mild Cognitive Impairment, Alzheimer Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
- Trial name
- NCT06400368
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NeuroVision Imaging
Mild Cognitive Impairment, Dementia
Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment
Validate speech analysis AI models: To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia.
- Trial name
- NCT05340218
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Accexible
Alzheimer Disease, Mild Cognitive Impairment
Software Validation Study-Cognitive Status Indicator
The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- REMIND-V (NCT06809725)
- Testing
- SPARK Cognitive Status Indicator (software support data collected via EEG)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
The purpose of this study is to test a new computerized training program as well as to find out whether the computer training might help people who have schizophrenia.
- Trial name
- TARA (NCT01773239)
- Testing
- TARA computer-based exercises
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Alzheimer's Type Dementia
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
- Trial name
- NCT01404169
- Testing
- E2020
- Where
- 32 sites in China
- Volunteers
- 260 people
- Sponsor
- Eisai Limited
Cognitive Impairment, Mild Cognitive Impairment
Assessing Performance on Speech Tasks Via Crowdsourced Participants
The purpose of the study is to examine the properties of the Automatic Story Recall Test (ASRT) and its parallel variants, as well as letter fluency and category fluency cognitive tests.
- Trial name
- AMYWEB (NCT05298501)
- Testing
- No intervention/exposure
- Where
- United Kingdom
- Volunteers
- 1,034 people
- Sponsor
- Novoic Limited
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience